Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.
  • Drug Patent & Exclusivity Expiration Report - Week of Nov 11 2024

    2024-11-11

    This week, there are 9 drugs in the patent and exclusivity list. They are: - JANSSEN PHARMACEUTICALS INC's XARELTO, containing active ingredient RIVAROXABAN - KYOWA KIRIN INC's NOURIANZ, containing active ingredient ISTRADEFYLLINE - SEAGEN INC's TUKYSA, containing active ingredient TUCATINIB - VANDA PHARMACEUTICALS INC's PONVORY, containing active ingredient PONESIMOD - AVEO PHARMACEUTICALS INC's FOTIVDA, containing active ingredient TIVOZANIB HYDROCHLORIDE - BIOMARIN PHARMACEUTICAL INC's KUVAN, containing active ingredient SAPROPTERIN DIHYDROCHLORIDE - PROVENSIS LTD's VARITHENA, containing active ingredient POLIDOCANOL - BEIGENE USA INC's BRUKINSA, containing active ingredient ZANUBRUTINIB - SHIONOGI INC's FETROJA, containing active ingredient CEFIDEROCOL SULFATE TOSYLATE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Nov 4 2024

    2024-11-04

    This week, there are 11 drugs in the patent and exclusivity list. They are: - BAUSCH AND LOMB INC's XIIDRA, containing active ingredient LIFITEGRAST - FRESENIUS KABI USA LLC's OMEGAVEN, containing active ingredient FISH OIL TRIGLYCERIDES - MYLAN SPECIALTY LP's TOBI PODHALER, containing active ingredient TOBRAMYCIN - ASTRAZENECA LP's SYMBICORT, containing active ingredient BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - ASTRAZENECA AB's BYETTA, containing active ingredient EXENATIDE SYNTHETIC - HOFFMANN-LA ROCHE INC's ALECENSA, containing active ingredient ALECTINIB HYDROCHLORIDE - HOFFMANN LA ROCHE INC's ZELBORAF, containing active ingredient VEMURAFENIB - GISKIT PHARMA BV's EXEM FOAM KIT, containing active ingredient AIR POLYMER-TYPE A - MERCK SHARP AND DOHME CORP's PREVYMIS, containing active ingredient LETERMOVIR - MERCK SHARP AND DOHME LLC's PREVYMIS, containing active ingredient LETERMOVIR - BRISTOL MYERS SQUIBB CO's SPRYCEL, containing active ingredient DASATINIB Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Oct 28 2024

    2024-10-28

    This week, there are 6 drugs in the patent and exclusivity list. They are: - ALEXZA PHARMACEUTICALS INC's ADASUVE, containing active ingredient LOXAPINE - ASTRAZENECA PHARMACEUTICALS LP's BRILINTA, containing active ingredient TICAGRELOR - CORMEDIX INC's DEFENCATH, containing active ingredient HEPARIN SODIUM; TAUROLIDINE - ABBVIE INC's VUITY, containing active ingredient PILOCARPINE HYDROCHLORIDE - SANOFI AVENTIS US LLC's AUBAGIO, containing active ingredient TERIFLUNOMIDE - ASTRAZENECA UK LTD's CALQUENCE, containing active ingredient ACALABRUTINIB Read More
  • Semaglutide: A Promising Frontier in Alzheimer's Disease Prevention

    2024-10-25

    We're excited to discuss groundbreaking research on semaglutide, the blockbuster medication that's showing promising potential in the fight against Alzheimer's disease (AD) Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Oct 21 2024

    2024-10-22

    This week, there are 3 drugs in the patent and exclusivity list. They are: - BRISTOL-MYERS SQUIBB CO's ABRAXANE, containing active ingredient PACLITAXEL - VERTEX PHARMACEUTICALS INC's TRIKAFTA (COPACKAGED), containing active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - BAUSCH AND LOMB INC's XIPERE, containing active ingredient TRIAMCINOLONE ACETONIDE Read More
  • Oral SERD Therapy: Elacestrant's Impact on Metastatic Breast Cancer

    2024-10-10

    IntroductionBreast cancer remains a significant global health challenge, with over 2.3 million new cases diagnosed worldwide in 2022, according to the IARC. The disease burden is disproportionately higher in countries with medium or low levels of the Human Development Index (HDI), where access to in Read More
  • Drug Briefing: Elacestrant

    2024-10-08

    Query Drug:ElacestrantQuery Time:2024-10-08 16:20:43*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest Read More
  • Alopecia Areata: More Than Just Hair Loss

    2024-09-20

    Alopecia areata (AA) is an autoimmune disorder that goes far beyond mere hair loss. While the physical manifestation of patchy or complete hair loss is its most visible symptom, the impact of AA extends deep into the psychological realm, affecting millions worldwide.Understanding Alopecia AreataAlop Read More
  • Drug Briefing: Ritlecitinib

    2024-09-13

    Query Drug:RitlecitinibQuery Time:2024-09-13 16:17:58*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest Read More
  • Total 12 pages  Go to Page
  • Go